The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01465763
Recruitment Status : Completed
First Posted : November 6, 2011
Results First Posted : June 7, 2016
Last Update Posted : June 7, 2016
Sponsor:
Information provided by (Responsible Party):
Pfizer

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition Ulcerative Colitis
Interventions Drug: tofacitinib
Drug: Placebo
Enrollment 614
Recruitment Details  
Pre-assignment Details Participants were randomized to tofacitinib 10 milligram (mg) or placebo twice a day (BID)(4:1 ratio) after protocol amendment 3, which removed tofacitinib 15 mg BID. Due to low participant numbers, tofacitinib 15 mg BID was excluded from efficacy analyses, but was included in participant flow, baseline characteristics and adverse events analyses.
Arm/Group Title Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID
Hide Arm/Group Description Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib 15 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Period Title: Overall Study
Started 476 16 122
Completed 445 15 118
Not Completed 31 1 4
Reason Not Completed
Withdrawal by Subject             4             0             1
Insufficient Clinical Response             11             0             1
Adverse Event             9             0             1
Other             2             0             0
Protocol Violation             4             1             1
Death             1             0             0
Arm/Group Title Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID Total
Hide Arm/Group Description Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib 15 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period. Total of all reporting groups
Overall Number of Baseline Participants 476 16 122 614
Hide Baseline Analysis Population Description
The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.
Age, Customized  
Measure Type: Number
Unit of measure:  Participants
 Number Analyzed 476 participants 16 participants 122 participants 614 participants
18 to 44 Years 295 11 72 378
45 to 64 Years 145 4 39 188
Greater Than or Equal to (>=) 65 Years 36 1 11 48
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 476 participants 16 participants 122 participants 614 participants
Female
199
  41.8%
7
  43.8%
45
  36.9%
251
  40.9%
Male
277
  58.2%
9
  56.3%
77
  63.1%
363
  59.1%
1.Primary Outcome
Title Percentage of Participants With Remission at Week 8
Hide Description Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS) included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
18.5 8.2
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on Cochran-Mantel-Haenszel (CMH) chi-square test stratified by prior treatment with anti-tumor necrosis factor (TNF), steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using Non-responder imputation (NRI).
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0070
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 10.3
Confidence Interval (2-Sided) 95%
4.3 to 16.3
Estimation Comments [Not Specified]
2.Secondary Outcome
Title Percentage of Participants Achieving Mucosal Healing at Week 8
Hide Description Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
31.3 15.6
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0005
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 15.7
Confidence Interval (2-Sided) 95%
8.1 to 23.4
Estimation Comments [Not Specified]
3.Secondary Outcome
Title Percentage of Participants Achieving Clinical Response at Week 8
Hide Description Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
59.9 32.8
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value <0.0001
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 27.1
Confidence Interval (2-Sided) 95%
17.7 to 36.5
Estimation Comments [Not Specified]
4.Secondary Outcome
Title Percentage of Participants With Endoscopic Remission at Week 8
Hide Description Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
6.7 1.6
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0345
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 5.1
Confidence Interval (2-Sided) 95%
1.9 to 8.3
Estimation Comments [Not Specified]
5.Secondary Outcome
Title Percentage of Participants With Clinical Remission at Week 8
Hide Description Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
18.5 8.2
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0070
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 10.3
Confidence Interval (2-Sided) 95%
4.3 to 16.3
Estimation Comments [Not Specified]
6.Secondary Outcome
Title Percentage of Participants With Symptomatic Remission at Week 8
Hide Description Symptomatic remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
11.8 5.7
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0601
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 6.0
Confidence Interval (2-Sided) 95%
1.0 to 11.1
Estimation Comments [Not Specified]
7.Secondary Outcome
Title Percentage of Participants With Deep Remission at Week 8
Hide Description Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Measure Type: Number
Unit of Measure: percentage of participants
6.5 0
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments P-value based on CMH chi-square test stratified by prior treatment with anti-TNF, steroid use at baseline and geographic region. Difference and its 95% CI based on normal approximation for the difference in binomial proportions. Missing data were imputed using NRI.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0043
Comments [Not Specified]
Method CMH Chi-square test
Comments [Not Specified]
Method of Estimation Estimation Parameter Percent Difference
Estimated Value 6.5
Confidence Interval (2-Sided) 95%
4.3 to 8.7
Estimation Comments [Not Specified]
8.Secondary Outcome
Title Partial Mayo Scores
Hide Description A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
Time Frame Baseline, Weeks 2, 4, 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Mean (Standard Deviation)
Unit of Measure: units on a scale
Baseline: (n= 475, 121) 6.3  (1.2) 6.5  (1.2)
At Week 2: (n= 465, 122) 4.2  (2.2) 5.2  (2.1)
At Week 4: (n= 461, 118) 3.5  (2.3) 4.8  (2.4)
At week 8: (n= 449, 119) 3.2  (2.4) 4.8  (2.5)
9.Secondary Outcome
Title Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8
Hide Description Change in partial mayo scores at weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (mayo score without endoscopy) graded from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each grading from 0 to 3 with higher scores indicating more severe disease.
Time Frame Baseline, Weeks 2, 4, 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Least Squares Mean (Standard Error)
Unit of Measure: units on a scale
Change at Week 2: (n= 464, 121) -2.1  (0.1) -1.2  (0.2)
Change at week 4: (n= 460, 117) -2.8  (0.1) -1.6  (0.2)
Change at week 8: (n= 448, 118) -3.1  (0.1) -1.6  (0.2)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments At Week 2: The change from baseline was analyzed using mixed effect model with treatment group, prior treatment with antiTNF, steroid use at baseline, geographic region, visit and visit by treatment group all as fixed effects, and participants as a random effect.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value <0.0001
Comments [Not Specified]
Method Mixed-Effects Model
Comments [Not Specified]
Method of Estimation Estimation Parameter Least Square Mean Difference
Estimated Value -0.9
Confidence Interval (2-Sided) 95%
-1.3 to -0.5
Parameter Dispersion
Type: Standard Error of the mean
Value: 0.2
Estimation Comments [Not Specified]
Hide Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments At Week 4: The change from baseline was analyzed using mixed effect model with treatment group, prior treatment with antiTNF, steroid use at baseline, geographic region, visit and visit by treatment group all as fixed effects, and participants as a random effect.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value <0.0001
Comments [Not Specified]
Method Mixed-Effects Model
Comments [Not Specified]
Method of Estimation Estimation Parameter Least Square Mean Difference
Estimated Value -1.1
Confidence Interval (2-Sided) 95%
-1.5 to -0.7
Parameter Dispersion
Type: Standard Error of the mean
Value: 0.2
Estimation Comments [Not Specified]
Hide Statistical Analysis 3
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments At Week 8: The change from baseline was analyzed using mixed effect model with treatment group, prior treatment with antiTNF, steroid use at baseline, geographic region, visit and visit by treatment group all as fixed effects, and participants as a random effect.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value <0.0001
Comments [Not Specified]
Method Mixed-Effects Model
Comments [Not Specified]
Method of Estimation Estimation Parameter Least Square Mean Difference
Estimated Value -1.5
Confidence Interval (2-Sided) 95%
-1.9 to -1.1
Parameter Dispersion
Type: Standard Error of the mean
Value: 0.2
Estimation Comments [Not Specified]
10.Secondary Outcome
Title Change From Baseline in Total Mayo Scores at Week 8
Hide Description Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease.
Time Frame Baseline, Week 8
Hide Outcome Measure Data
Hide Analysis Population Description
FAS included all participants randomly assigned to either tofacitinib 10 mg BID or placebo BID. Here, 'n' signifies those participants who were evaluable at specified time point for each arm, respectively.
Arm/Group Title Tofacitinib 10 mg BID Placebo BID
Hide Arm/Group Description:
Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period.
Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
Overall Number of Participants Analyzed 476 122
Mean (Standard Deviation)
Unit of Measure: units on a scale
Baseline (n= 472, 121) 9.0  (1.4) 9.1  (1.4)
Change at Week 8 (n= 443, 117) -3.8  (2.8) -1.9  (2.5)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Tofacitinib 10 mg BID, Placebo BID
Comments The change from Baseline at Week 8 was analyzed using an analysis of covariance (ANCOVA) model with treatment group, prior treatment with anti-TNF, steroid use at baseline and geographic region as factors and baseline as a covariate based on the observed-case data.
Type of Statistical Test Superiority or Other
Comments [Not Specified]
Statistical Test of Hypothesis P-Value <0.0001
Comments [Not Specified]
Method ANCOVA
Comments [Not Specified]
Method of Estimation Estimation Parameter Least Square Mean Difference
Estimated Value -1.9
Confidence Interval (2-Sided) 95%
-2.5 to -1.4
Parameter Dispersion
Type: Standard Error of the mean
Value: 0.3
Estimation Comments [Not Specified]
Time Frame Baseline up to Day 98
Adverse Event Reporting Description The same event may appear as both an adverse event (AE) and an serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study.
 
Arm/Group Title Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID
Hide Arm/Group Description Participants received tofacitinib 10 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib 15 mg, tablets, orally, BID for 9 weeks of double blind treatment period. Participants received tofacitinib-matched placebo tablets, orally, BID for 9 weeks of double blind treatment period.
All-Cause Mortality
Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/--   --/-- 
Hide Serious Adverse Events
Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   16/476 (3.36%)   0/16 (0.00%)   5/122 (4.10%) 
Cardiac disorders       
Acute coronary syndrome * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Gastrointestinal disorders       
Colitis ulcerative * 1  5/476 (1.05%)  0/16 (0.00%)  2/122 (1.64%) 
Intestinal perforation * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
General disorders       
Malaise * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Immune system disorders       
Drug hypersensitivity * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Infections and infestations       
Anal abscess * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Cellulitis * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Clostridium difficile infection * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Febrile infection * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Otitis externa * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Pneumonia * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Injury, poisoning and procedural complications       
Animal bite * 1  0/476 (0.00%)  0/16 (0.00%)  1/122 (0.82%) 
Joint injury * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Musculoskeletal and connective tissue disorders       
Arthralgia * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Reproductive system and breast disorders       
Vulva cyst * 1  0/476 (0.00%)  0/16 (0.00%)  1/122 (0.82%) 
Respiratory, thoracic and mediastinal disorders       
Pulmonary embolism * 1  0/476 (0.00%)  0/16 (0.00%)  1/122 (0.82%) 
Skin and subcutaneous tissue disorders       
Drug eruption * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Vascular disorders       
Aortic dissection * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
Temporal arteritis * 1  1/476 (0.21%)  0/16 (0.00%)  0/122 (0.00%) 
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA v18.0
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Tofacitinib 10 mg BID Tofacitinib 15 mg BID Placebo BID
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   148/476 (31.09%)   12/16 (75.00%)   38/122 (31.15%) 
Blood and lymphatic system disorders       
Anaemia * 1  11/476 (2.31%)  1/16 (6.25%)  6/122 (4.92%) 
Gastrointestinal disorders       
Colitis ulcerative * 1  6/476 (1.26%)  1/16 (6.25%)  3/122 (2.46%) 
Flatulence * 1  2/476 (0.42%)  1/16 (6.25%)  1/122 (0.82%) 
Gastrooesophageal reflux disease * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
Nausea * 1  15/476 (3.15%)  1/16 (6.25%)  5/122 (4.10%) 
General disorders       
Fatigue * 1  10/476 (2.10%)  1/16 (6.25%)  4/122 (3.28%) 
Pyrexia * 1  14/476 (2.94%)  1/16 (6.25%)  3/122 (2.46%) 
Infections and infestations       
Folliculitis * 1  9/476 (1.89%)  1/16 (6.25%)  0/122 (0.00%) 
Gastroenteritis * 1  7/476 (1.47%)  1/16 (6.25%)  2/122 (1.64%) 
Nasopharyngitis * 1  34/476 (7.14%)  3/16 (18.75%)  9/122 (7.38%) 
Sinusitis * 1  2/476 (0.42%)  2/16 (12.50%)  1/122 (0.82%) 
Upper respiratory tract infection * 1  15/476 (3.15%)  1/16 (6.25%)  1/122 (0.82%) 
Investigations       
Blood creatine phosphokinase increased * 1  12/476 (2.52%)  1/16 (6.25%)  0/122 (0.00%) 
Liver function test abnormal * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
White blood cell count increased * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
Musculoskeletal and connective tissue disorders       
Myalgia * 1  2/476 (0.42%)  1/16 (6.25%)  2/122 (1.64%) 
Nervous system disorders       
Headache * 1  37/476 (7.77%)  0/16 (0.00%)  8/122 (6.56%) 
Psychiatric disorders       
Anxiety * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
Depressed mood * 1  1/476 (0.21%)  1/16 (6.25%)  1/122 (0.82%) 
Renal and urinary disorders       
Dysuria * 1  1/476 (0.21%)  1/16 (6.25%)  0/122 (0.00%) 
Haematuria * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
Skin and subcutaneous tissue disorders       
Acne * 1  10/476 (2.10%)  3/16 (18.75%)  0/122 (0.00%) 
Alopecia * 1  5/476 (1.05%)  1/16 (6.25%)  1/122 (0.82%) 
Dermatitis acneiform * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
Night sweats * 1  0/476 (0.00%)  1/16 (6.25%)  0/122 (0.00%) 
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA v18.0
[Not Specified]
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer Inc.
Phone: 1-800-718-1021
EMail: ClinicalTrials.gov_Inquiries@pfizer.com
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01465763    
Other Study ID Numbers: A3921094
2011-004578-27 ( EudraCT Number )
OCTAVEINDUCTION1 ( Other Identifier: Alias Study Number )
First Submitted: October 21, 2011
First Posted: November 6, 2011
Results First Submitted: May 1, 2016
Results First Posted: June 7, 2016
Last Update Posted: June 7, 2016